<p>Sun Pharma on Friday reported a 43 per cent rise in consolidated net profit at Rs 2,061 crore for the June quarter, riding on robust sales across markets.</p>.<p>The Mumbai-based company had posted a net profit of Rs 1,444 crore in April-June 2021-22.</p>.<p>Total revenue from operations rose to Rs 10,762 crore in the period under review from Rs 9,719 crore earlier, Sun Pharmaceutical Industries said in a regulatory filing.</p>.<p>"For Q1, all our businesses recorded good growth, driven by a combination of sustained scale-up for our speciality business and all-round growth across markets," Managing Director Dilip Shanghvi said.</p>.<p>Speciality business grew 29 per cent driven by Ilumya, Cequa, Odomzo and Winlevi, he added.</p>.<p>"Our India business continues to grow faster than the market, leading to an increase in market share. We have been able to report healthy margins despite rising costs," Shanghvi said.</p>.<p>The company continues to focus on expanding its global speciality business, growing all its businesses and improving market share, he added.</p>.<p>Shares of the company were trading 3.88 per cent up at Rs 929.5 apiece on the BSE.</p>
<p>Sun Pharma on Friday reported a 43 per cent rise in consolidated net profit at Rs 2,061 crore for the June quarter, riding on robust sales across markets.</p>.<p>The Mumbai-based company had posted a net profit of Rs 1,444 crore in April-June 2021-22.</p>.<p>Total revenue from operations rose to Rs 10,762 crore in the period under review from Rs 9,719 crore earlier, Sun Pharmaceutical Industries said in a regulatory filing.</p>.<p>"For Q1, all our businesses recorded good growth, driven by a combination of sustained scale-up for our speciality business and all-round growth across markets," Managing Director Dilip Shanghvi said.</p>.<p>Speciality business grew 29 per cent driven by Ilumya, Cequa, Odomzo and Winlevi, he added.</p>.<p>"Our India business continues to grow faster than the market, leading to an increase in market share. We have been able to report healthy margins despite rising costs," Shanghvi said.</p>.<p>The company continues to focus on expanding its global speciality business, growing all its businesses and improving market share, he added.</p>.<p>Shares of the company were trading 3.88 per cent up at Rs 929.5 apiece on the BSE.</p>